Takeda Pharmaceutical Co. Ltd. lists three research areas – GI, oncology and CNS – from which it wants to grow a more specialty-based business, but the Tokyo, Japan-based business also remains active in researching novel vaccines, including a potential dengue vaccine, TAK-003, for which it has just released an interim 18-month analysis of Phase II data that backed the start of the Phase III TIDES study in September 2016.
Importantly, Takeda reports that children receiving TAK-003 in dengue-endemic areas in the Dominican Republic, Panama and the Philippines, as part...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
